Asymchem, an end-to-end contract development and manufacturing organisation (CDMO) has appointed Dr Cheng Yi Chen as the Chief Technology Officer of the Small-Molecule sector.
In this position, Dr Cheng Yi Chen will provide technical support to the group’s chemical small molecule sales in the European and United States markets.
He will be actively involved in technical communications for key mid-to-late-stage clinical projects spanning Europe and the US, as well as facilitating collaborations with new clients.
Dr Yi Chen will also offer guidance to the China Core Team on project-related technical matters and supervise technical operations at small-molecule laboratories and pilot production sites throughout Europe.
Dr. Chen has previously worked at Merck Research Laboratories, Janssen Pharmaceuticals of Johnson & Johnson, Mirati Therapeutics and Bristol Myers Squibb before joining Asymchem.
He has extensive experience designing, developing and implementing robust, cost-effective and green manufacturing routes for small molecule APIs, ensuring CMC compliance and quality, collaborating with cross-functional drug development teams and external partners, and supporting regulatory filings.
